Nxera Pharma Co., Ltd.
SOLTF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$11,303 | -$2,377,000 | -$760,000 | -$1,335,000 |
| Dep. & Amort. | $7,477 | $1,095,000 | $1,082,000 | $1,003,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | -$388,000 | $388,000 | -$1,025,000 |
| Change in WC | -$7,929 | -$2,458,000 | $2,599,000 | -$6,736,000 |
| Other Non-Cash | -$8,362 | $4,126,751 | -$2,696,000 | -$2,877,000 |
| Operating Cash Flow | -$20,118 | -$180,000 | $613,000 | -$10,970,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$710 | -$90,000 | -$109,000 | -$153,000 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $291 | $0 | $0 | $0 |
| Other Inv. Act. | $88 | $89,431 | $3,706,000 | -$4,791,000 |
| Investing Cash Flow | -$331 | -$569 | $3,597,000 | -$4,944,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$9,802 | -$1,227,000 | -$1,673,000 | -$622,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$1,514 | $1,215,363 | $0 | -$1,052,000 |
| Financing Cash Flow | -$11,316 | -$11,637 | -$1,673,000 | -$1,674,000 |
| Forex Effect | -$4,805 | $12,677 | -$340,000 | $988,000 |
| Net Chg. in Cash | -$36,570 | -$778 | $34,465,000 | -$48,868,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $228,966 | $229,744 | $0 | $48,868,000 |
| End Cash | $192,396 | $228,966 | $34,465,000 | $0 |
| Free Cash Flow | -$20,807 | -$270,000 | $504,000 | -$11,123,000 |